Eisai, a global leader in neurology therapeutics, needed a real-world dataset to assess seizure outcomes for their epilepsy drug more precisely. Their existing approach involved stitching disparate datasets from various vendors, leading to delays, high costs, and limited confidence in the findings because of the inability to link the various datasets at patient-level. Embleema delivered a unified, patient-level dataset within 3 months, empowering Eisai with statistically robust evidence and accelerating insights.

Watch the Eisai case study overview video instead

The Challenge

Eisai's Clinical Research leadership faced a critical gap: no available real-world dataset could deliver comprehensive treatment, diagnostic and demographics data with seizure data —a key metric of treatment efficacy - at the patient level. Existing vendor datasets had one or the other data type—forcing Eisai's data team to statistically correlate multiple sources together, increasing cost, time, and risk of error in the evidence generated.

The Solution

Eisai partnered with Embleema to leverage the BET platform, enabling seamless collection of linked, patient-level Real World Data (EMR, PROs, seizure tracking, SDOH, provider type, and comorbidities). BET is a robust research platform that not only supports patient self-management but also supports clinical trial recruitment. Both an epilepsy registry and patient community, it was co-developed with the Epilepsy Foundation and leading epilepsy researcher Dr. Jacqueline French, President of the Epilepsy Study Consortium.

Embleema's patient app allows epilepsy patients to track their medical history, symptoms, and seizures, while securely sharing their data with their care team.

For patients, the BET platform enables individuals with epilepsy to log seizures, track medications, monitor symptoms, and access personalized insights—all within a secure, user-friendly environment. The platform seamlessly integrates data from connected devices and medical records, providing comprehensive tracking without gaps. The multilingual, mobile-first design ensures accessibility for a diverse community.

For pharmaceutical companies, BET delivers a comprehensive real-world dataset at the patient-level, specifically designed for epilepsy. Additionally, for pharmaceutical companies it offers a highly engaged and pre-qualified patient community, enabling faster, more effective recruitment for research studies. This dual purpose—patient empowerment and real-world evidence generation—makes BET an essential tool for advancing precision medicine.

Request a custom demo

The Results

Within just three months, Embleema delivered a unified dataset that dramatically improved evidence precision and analytic value.

• A linked, patient-level dataset covering EMRs, patient-reported outcomes (PROs), and seizure tracking

• >95% of participants contributed seizure outcomes and survey data

• >70% shared their full medical records

• Delivered continuous seizure monitoring linked to treatment and demographics

• Dataset supported high-quality statistical analysis for RWE generation

Impact

• Faster time to high-quality insight with no data stitching

• Stronger confidence in the evidence generated

• Dataset positioned for use in regulatory discussions, publication, or trial endpoint design

• Initial results were shared with the Epilepsy Study Consortium and the Epilepsy Foundation, validating the scientific impact of the collaboration

Request an exploratory call

Scientific Alignment

The BET platform used by Eisai is also the foundation of the Human Epilepsy Project, active at over 20 leading research centers (NYU Langone, Mayo Clinic, UPenn).

Why Embleema

Unlike other platforms, Embleema provided:

• Rapid deployment (3 months)

• Comprehensive disease-specific patient-level data by-design linkage

• Scientific-grade data quality at scale

Ready to learn about how Embleema delivers regulatory-ready RWE and helps reduce trial costs?